In conclusion, if a specific and significant contribution of LukED to the resistance and persistence of S. aureus in patients with CRSwNP and its relapsing forms might be demonstrated, the availability of a CCR5 antagonist such as maraviroc, chemokine derivatives and monoclonal antibodies might open the road to speculate on a potential use for these molecules in clinical settings, although effectiveness and safety should be assessed in each specific clinical scenario. The gene discussed is CCR5; the disease is chronic rhinosinusitis with nasal polyps.